{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:34:01Z","timestamp":1791196441220,"version":"4.1.0"},"reference-count":23,"publisher":"European Respiratory Society (ERS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2012,1,11]]},"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH).<\/jats:p>\n                  <jats:p>43 adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and\/or a phosphodiesterase type-5 inhibitor therapy) were randomised three to one to receive either selexipag or placebo. Dosage was up-titrated in 200-\u03bcg increments from 200 \u03bcg twice daily on day 1 to the maximum tolerated dose by day 35 (maximum allowed dose of 800 \u03bcg twice daily). Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analysed in the per protocol set first and then in the all-treated set to assess robustness of results.<\/jats:p>\n                  <jats:p>A statistically significant 30.3% reduction in geometric mean pulmonary vascular resistance was observed after 17 weeks' treatment with selexipag compared with placebo (95% confidence limits -44.7\u2013 -12.2; p=0.0045, Wilcoxon rank sum test). This was supported by a similar result from the all-treated set. Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect.<\/jats:p>\n                  <jats:p>Our results encourage the further investigation of selexipag for the treatment of PAH.<\/jats:p>","DOI":"10.1183\/09031936.00137511","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T22:59:04Z","timestamp":1330037944000},"page":"874-880","source":"Crossref","is-referenced-by-count":271,"title":["Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension"],"prefix":"10.1183","volume":"40","author":[{"given":"G\u00e9rald","family":"Simonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00f3f","family":"Karl\u00f3cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Degano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kurzyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2012,2,23]]},"reference":[{"key":"2024102021021053000_40.4.874.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139009"},{"key":"2024102021021053000_40.4.874.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192230"},{"key":"2024102021021053000_40.4.874.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270202"},{"key":"2024102021021053000_40.4.874.4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF03256644","article-title":"Prostanoids for pulmonary arterial hypertension","volume":"2","author":"Gali\u00e8","year":"2003","journal-title":"Am J Respir Med"},{"key":"2024102021021053000_40.4.874.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.036"},{"key":"2024102021021053000_40.4.874.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.017"},{"key":"2024102021021053000_40.4.874.7","doi-asserted-by":"publisher","DOI":"10.1038\/263663a0"},{"key":"2024102021021053000_40.4.874.8","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.26.2.4695"},{"key":"2024102021021053000_40.4.874.9","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.5.1147"},{"key":"2024102021021053000_40.4.874.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707413"},{"key":"2024102021021053000_40.4.874.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2024102021021053000_40.4.874.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029100.82385.58"},{"key":"2024102021021053000_40.4.874.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"2024102021021053000_40.4.874.14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21693\/1933-088X-8.1.32","article-title":"Update on the development of oral prostacyclin analogs for the treatment of PAH","volume":"8","author":"White","year":"2009","journal-title":"Adv Pulmonary Hypertens"},{"key":"2024102021021053000_40.4.874.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.07.015"},{"key":"2024102021021053000_40.4.874.16","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.124248"},{"key":"2024102021021053000_40.4.874.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"2024102021021053000_40.4.874.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi410"},{"key":"2024102021021053000_40.4.874.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"2024102021021053000_40.4.874.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380501"},{"key":"2024102021021053000_40.4.874.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2024102021021053000_40.4.874.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"2024102021021053000_40.4.874.23","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.138305"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00137511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:35:33Z","timestamp":1740360933000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00137511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,9,30]]},"published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1183\/09031936.00137511"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00137511","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.722034955.793525233","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}